Chiron Recovery Implements Medically Assisted Treatment (MAT) Program to Treat Opioid Addiction

75% success rates in studies of Buprenorphine when combined with traditional treatment.

PALM BEACH GARDENS, Fla., Feb. 21, 2018 /PRNewswire/ -- Chiron Recovery, an evidenced-based dual diagnosis treatment facility, recently implemented a MAT program for the treatment of opioid addiction. At Chiron Recovery, we believe that relying solely on an abstinence-based program incorrectly insinuates that addiction is a failure of willpower or morals and only further stigmatizes addiction and its treatment. Addiction is a chronic disease and just like other chronic diseases, we are confident that successful treatment exists in a combination of medication merged with the current psychosocial services including therapy and 12 step programs. We strongly believe based on numerous evidence-based studies that Medically Assisted Treatment (MAT) is a necessary component of treatment for our current opioid epidemic. We are not alone in this belief as the federal government and some of the largest public health organizations in the United States including the Centers for Disease Control and Prevention (CDC), the National Institute on Drug Abuse (NIDA), and the World Health Organization (WHO) also support and recommend MAT.

We utilize buprenorphine combined with naloxone due to its accessibility, low risk for misuse, abuse, and overdose, and success rates when compared to traditional treatment or other approved MAT options including methadone and naltrexone.

Contact:For further information about this program please visit our website at https://www.chironrecovery.com or call 888-403-7062 to speak with a clinical specialist about a treatment program.

Related Links

https://www.chironrecovery.com/

View original content:http://www.prnewswire.com/news-releases/chiron-recovery-implements-medically-assisted-treatment-mat-program-to-treat-opioid-addiction-300602080.html

SOURCE Chiron Recovery

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...